TABLE 2.
Distribution of T3SS virulotypes among P. aeruginosa clinical isolates from companion animals according to antimicrobial resistance
| Antimicrobial(s) | No. (%) of isolates by T3SS virulotype |
P value for comparison between exoU+/exoS− and exoU−/exoS+ | |||
|---|---|---|---|---|---|
| exoU+/exoS− (n = 35) | exoU−/exoS+ (n = 195) | exoU+/exoS+ (n = 3) | exoU−/exoS− (n = 7) | ||
| Piperacillin | 6 (17) | 11 (6) | 0 | 0 | 0.02843 |
| Piperacillin-tazobactam | 6 (17) | 12 (6) | 0 | 0 | 0.03787 |
| Ceftazidime | 1 (3) | 5 (3) | 0 | 0 | |
| Cefepime | 1 (3) | 12 (6) | 0 | 0 | |
| Aztreonam | 8 (23) | 49 (25) | 0 | 0 | |
| Imipenem | 4 (11) | 41 (21) | 0 | 0 | |
| Meropenem | 2 (6) | 11 (6) | 0 | 0 | |
| Gentamicin | 6 (17) | 8 (4) | 0 | 0 | 0.009844 |
| Amikacin | 0 (0) | 2 (1) | 0 | 0 | |
| Tobramycin | 3 (9) | 3 (2) | 0 | 0 | 0.04685 |
| Ciprofloxacin | 6 (17) | 60 (31) | 0 | 1 | |
| Colistin | 0 (0) | 1 (1) | 0 | 0 | |